Search Results for: pcsa

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has reported its financial and corporate results for the first quarter of 2021, the period ended March 31, 2021. In the report, PCSA noted that its clinical drug pipeline is … Continue reading “QualityStocksNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Q1 2021 Financial, Corporate Report”

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that it will host a conference call and live webcast to discuss its first quarter 2021 results and provide an update on its clinical pipeline. The event is … Continue reading “QualityStocksNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Host Conference/Webcast to Discuss Q1 Results, Provide Clinical Pipeline Update”

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and quality of life for patients who have unmet medical needs, has reported its financial numbers for the year ending Dec. 31, 2020; the company also reported a corporate update. High on the list of noteworthy achievements for the year 2020 … Continue reading “QualityStocksNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases FY 2020 Financial, Corporate Report”

Processa Pharmaceuticals Inc. (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, has scheduled a conference call to discuss its fourth-quarter financial report as well as to provide a drug-development update. The conference call and life webcast will be available to … Continue reading “QualityStocksNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Conference Call to Discuss Q4 Numbers, Clinical Pipeline Update”

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical stage company developing drugs for patients who have unmet medical conditions that require better treatment options to improve a patient’s survival and/or quality of life, today announced that it has selected five U.S. clinical sites to enroll patients with ulcerative necrobiosis lipoidica for the company’s Phase 2B trial. In … Continue reading “QualityStocksNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Sites for Phase 2B Clinical Trial”

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, has closed its previously announced private placement to institutional and accredited investors. According to the update, the company sold 1,321,132 shares of its common stock at a purchase price of … Continue reading “QualityStocksNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Closes $10.2M Private Placement”

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a research report by Encode Ideas L.P., a health care focused research firm. The full research publication is available at https://ibn.fm/NqQs7. The report reads, “Processa’s pipeline is … Continue reading “QualityStocksNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Research Report”

Processa Pharmaceuticals Inc. (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, has executed a securities purchase agreement. The agreement is intended to raise gross proceeds of $10.2 million through the sale of 1,321,132 shares. The shares will be sold at … Continue reading “QualityStocksNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Executes Purchase Agreement to Raise $10.2M”

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, today announced that management will present at the H.C. Wainwright BIOCONNECT 2021 Virtual Conference. According to the update, the presentation is now available for on-demand listening by visiting https://ibn.fm/OVOdD. In … Continue reading “QualityStocksNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at H.C. Wainwright BIOCONNECT 2021”

Processa Pharmaceuticals (NASDAQ: PCSA), a clinical-stage biopharmaceutical company developing products to improve the survival and/or quality of life for patients who have unmet medical needs, was featured in a research report by the Benchmark Company LLC. The report, titled “Processa Pharmaceuticals Inc. (PCSA) Processing Assets to the FDA; Initiate at Buy,” lists a $15 price … Continue reading “QualityStocksNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Featured in Research Report”